APA (7th ed.) Citation

Mele, G., Cascavilla, N., Di Renzo, N., Guarini, A., Mazza, P., Melillo, L., . . . Pastore, D. (2022). Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma. Annals of Hematology, 101(8), 1727. https://doi.org/10.1007/s00277-022-04857-0

Chicago Style (17th ed.) Citation

Mele, G., et al. "Daratumumab Plus Bortezomib or Daratumumab Plus Lenalidomide as Salvage Therapy for Patients with Myeloma." Annals of Hematology 101, no. 8 (2022): 1727. https://doi.org/10.1007/s00277-022-04857-0.

MLA (9th ed.) Citation

Mele, G., et al. "Daratumumab Plus Bortezomib or Daratumumab Plus Lenalidomide as Salvage Therapy for Patients with Myeloma." Annals of Hematology, vol. 101, no. 8, 2022, p. 1727, https://doi.org/10.1007/s00277-022-04857-0.